Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development and clinical-stage biotechnology company based in Sydney, Australia. News about Kazia typically centers on the progress of its investigational cancer therapies, particularly its lead program paxalisib, as well as pipeline additions such as EVT801 and a first-in-class PD-L1 protein degrader program.
Company announcements frequently highlight clinical and translational data for paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Recent news has included results from glioblastoma studies, early efficacy and biomarker findings in advanced triple-negative breast cancer and HER2-positive metastatic breast cancer, and mechanistic data showing reductions in circulating tumor cells and clusters, changes in tumor cell phenotypes, and reinvigoration of immune cell function.
Kazia’s news flow also covers regulatory and development strategy updates, such as its intention to request FDA Type C meetings to discuss overall survival data in newly diagnosed glioblastoma and potential regulatory pathways, as well as participation in initiatives like an Australian Medical Research Future Fund project using AI-enabled platforms to guide therapy sequencing in diffuse midline glioma and diffuse intrinsic pontine glioma.
Investors following KZIA news will also find information on capital markets activities, including private placements of equity securities, at-the-market offerings of American Depositary Shares, and Nasdaq listing compliance developments. Updates on the EVT801 VEGFR3 inhibitor program, the NDL2 PD-L1 degrader collaboration with QIMR Berghofer, and participation in major oncology conferences provide additional context on Kazia’s evolving pipeline and scientific positioning.
This news page aggregates these disclosures so readers can track key milestones in Kazia’s clinical programs, regulatory interactions, collaborations, and financing events over time.
Kazia Therapeutics (NASDAQ: KZIA) has been granted an additional 180-day extension by Nasdaq, until November 18, 2024, to comply with the Minimum Bid Price Requirement of $1.00 per share. Initially notified of the deficiency on November 20, 2023, Kazia failed to regain compliance by the original deadline of May 20, 2024. Despite this, Nasdaq extended the compliance period based on the company's adherence to other listing criteria and its intent to resolve the issue. Kazia may employ solutions like a ratio change of its American Depositary Shares (ADSs). Failure to comply could lead to delisting, though appeals are possible. The extension does not affect current operations or trading under the ticker 'KZIA' on The Nasdaq Capital Market.
Kazia Therapeutics reported successful completion of stage 1 of the EVT801 Phase 1 clinical trial in advanced cancer patients. The Safety Review Team confirmed meeting primary and secondary objectives, determining a recommended phase 2 dose at 400mg BID. EVT801 showed promising clinical activity, especially in patients with advanced ovarian cancer. The trial included 26 patients across six dosing cohorts, with EVT801 being well-tolerated. CEO Dr. John Friend emphasized the need for new therapies in high-grade serous ovarian cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.